Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting

Publication date: August 2021Source: IJC Heart & Vasculature, Volume 35Author(s): Lisa Riesinger, Claudia Strobl, David M. Leistner, Tommaso Gori, Ibrahim Akin, Michael Mehr, Antonia Kellnar, Amir A. Mahabadi, Harilaos Bogossian, Michael Block, Frank Edelmann, Nikolaus Sarafoff, Dirk Sibbing, Hüseyin Ince, Tienush Rassaf, Ulrich Mansmann, Julinda Mehilli, Stefan Kääb, Jörg Hausleiter, Steffen Massberg
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research